CAR7 Antibody
Description
Introduction to CAR T Cells
CAR T cells are genetically engineered T cells designed to recognize and attack cancer cells. They are equipped with chimeric antigen receptors (CARs) that allow them to bind to specific antigens on cancer cells, enhancing their ability to kill these cells . While there is no specific mention of a "CAR7 Antibody," CAR T cells targeting various antigens have shown promising results in treating different types of cancer.
Overview of CAR T Cell Therapy
CAR T cell therapy involves several steps:
-
Collection and Engineering: T cells are collected from a patient's blood, genetically modified to express CARs, and then expanded in number.
-
Targeting Antigens: CARs are designed to recognize specific antigens on cancer cells, such as CD19 for B cell malignancies.
-
Infusion: The engineered T cells are infused back into the patient to target and kill cancer cells .
Related Antibodies in Immunotherapy
Antibodies play a crucial role in immunotherapy, often used to block or target specific antigens. For example, anti-CD7 antibodies are used to prevent fratricide in CAR T cell production for T cell malignancies . Similarly, B7-H3-targeting antibodies have been developed for CAR T cell therapy against solid tumors .
Research Findings on CAR T Cells
Recent studies have shown promising results with CAR T cells targeting various antigens:
-
B7-H3 CAR T Cells: These have demonstrated potent antitumor effects in solid tumors, offering a potential pathway for clinical translation .
-
CD7 CAR T Cells: Blocking the CD7 antigen with antibodies can enhance CAR T cell production and efficacy for T cell acute lymphoblastic leukemia (T-ALL) .
Data Tables: CAR T Cell Therapy Overview
Given the lack of specific data on "CAR7 Antibody," here is a general overview of CAR T cell therapy in table format:
